Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anqi Ma

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Oncotarget|January 13, 2016
Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic targetPrasoon Agarwal, Mohammad Alzrigat, Alba Atienza Párraga, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2017
Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome InhibitionOla Rizq, Naoya Mimura, Motohiko Oshima, et al.
Journal of Medicinal Chemistry|November 3, 2016
Structure-Based Design of a Covalent Inhibitor of the SET Domain-Containing Protein 8 (SETD8) Lysine MethyltransferaseKyle V Butler, Anqi Ma, Wenyu Yu, et al.
Nature Chemical Biology|December 11, 2019
Discovery of a first-in-class EZH2 selective degraderAnqi Ma, Elias Stratikopoulos, Kwang-Su Park, et al.
Journal of Medicinal Chemistry|March 1, 2013
Exploiting an allosteric binding site of PRMT3 yields potent and selective inhibitorsFeng Liu, Fengling Li, Anqi Ma, et al.
Clinical Epigenetics|September 17, 2021
Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myelomaLaurie Herviou, Sara Ovejero, Fanny Izard, et al.
Journal of Medicinal Chemistry|February 16, 2026
Discovery of a Potent, Selective, and In Vivo Efficacious Covalent Inhibitor for Lysine Methyltransferase SETD8He Chen, Rudra Prasad Dutta, Zhizhong Li, et al.
Plos One|June 2, 2015
Cancer Cells Hijack PRC2 to Modify Multiple Cytokine PathwaysMohamed Abou El Hassan, Katherine Huang, Manoja B K Eswara, et al.
Blood|March 2, 2017
Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in miceQingrong Huang, Shan He, Yuanyuan Tian, et al.
Journal of Medicinal Chemistry|July 18, 2014
Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8Anqi Ma, Wenyu Yu, Fengling Li, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Oncotarget|January 13, 2016
Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic targetPrasoon Agarwal, Mohammad Alzrigat, Alba Atienza Párraga, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2017
Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome InhibitionOla Rizq, Naoya Mimura, Motohiko Oshima, et al.
Journal of Medicinal Chemistry|November 3, 2016
Structure-Based Design of a Covalent Inhibitor of the SET Domain-Containing Protein 8 (SETD8) Lysine MethyltransferaseKyle V Butler, Anqi Ma, Wenyu Yu, et al.
Nature Chemical Biology|December 11, 2019
Discovery of a first-in-class EZH2 selective degraderAnqi Ma, Elias Stratikopoulos, Kwang-Su Park, et al.
Journal of Medicinal Chemistry|March 1, 2013
Exploiting an allosteric binding site of PRMT3 yields potent and selective inhibitorsFeng Liu, Fengling Li, Anqi Ma, et al.
Clinical Epigenetics|September 17, 2021
Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myelomaLaurie Herviou, Sara Ovejero, Fanny Izard, et al.
Journal of Medicinal Chemistry|February 16, 2026
Discovery of a Potent, Selective, and In Vivo Efficacious Covalent Inhibitor for Lysine Methyltransferase SETD8He Chen, Rudra Prasad Dutta, Zhizhong Li, et al.
Plos One|June 2, 2015
Cancer Cells Hijack PRC2 to Modify Multiple Cytokine PathwaysMohamed Abou El Hassan, Katherine Huang, Manoja B K Eswara, et al.
Blood|March 2, 2017
Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in miceQingrong Huang, Shan He, Yuanyuan Tian, et al.
Journal of Medicinal Chemistry|July 18, 2014
Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8Anqi Ma, Wenyu Yu, Fengling Li, et al.
Pageof 6